Workflow
【安迪苏(600299.SH)】蛋氨酸量价高增驱动24年盈利跃升,逆势扩产彰显成长韧性——2024年度报告点评(赵乃迪/蔡嘉豪)
AdisseoAdisseo(SH:600299) 光大证券研究·2025-03-06 09:25

Core Viewpoint - The company demonstrated strong resilience in its performance for 2024, with significant growth in revenue and net profit, driven by robust demand in the methionine business and effective cost management [2][3]. Group 1: Financial Performance - In 2024, the company achieved operating revenue of 15.5 billion, a year-on-year increase of 18% [2] - The net profit attributable to shareholders reached 1.2 billion, reflecting a remarkable year-on-year growth of 2209% [2] - The adjusted net profit after excluding non-recurring items was 1.35 billion, showing a staggering year-on-year increase of 10259% [2] - In Q4 alone, the company recorded operating revenue of 4.2 billion, up 17% year-on-year, but a 49% decline quarter-on-quarter [2] Group 2: Methionine Business Growth - The methionine business experienced strong growth, with both liquid and solid methionine sales reaching historical highs, resulting in a 24% year-on-year increase in revenue from this segment [3] - The company successfully improved its gross margin despite rising raw material prices, showcasing its effective supply chain management and cost transfer capabilities [3] - The vitamin business is expected to see a cyclical recovery, potentially injecting new momentum into future performance [3] Group 3: Market Dynamics and Pricing - Major players in the methionine market, such as Andisoo and Evonik, have raised prices, indicating a potential recovery in methionine prices after a period of decline [4] - As of March 5, 2025, the average domestic price of methionine was 21.35 yuan/kg, an increase of 8% from the beginning of the year [4] - The methionine market is expected to stabilize and recover due to improved supply-demand dynamics and delayed production from new capacities [4] Group 4: Capacity Expansion and Competitive Position - The company has increased its market share in methionine from 23% in 2012 to 28% in 2023, solidifying its competitive advantage [5] - A new solid methionine plant with an annual capacity of 150,000 tons is planned in Quanzhou, expected to be operational by 2027, which will enhance the company's cost advantages and service capabilities [6] - The company aims to further strengthen its market position in the Asia-Pacific region through this expansion [6]